12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALN-TTR02: Phase II started

Alnylam began an open-label, dose-escalation Phase II trial to evaluate IV ALN-TTR02 every 4 weeks for 2 cycles in about...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >